Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2

  • Technology appraisal guidance
  • TA257
  • Published: 

Tools and resources

Guidance into practice